Cialis Real-World Response Rate: What the Data and Patient Reviews Actually Show

Tadalafil (brand name Cialis, PDE5 inhibitor class) is FDA-approved for erectile dysfunction as an on-demand tablet since 2003 and as a once-daily low-dose tablet (2.5 mg or 5 mg) since 2008; the 5 mg daily dose is also approved for benign prostatic hyperplasia symptoms. The question most readers actually have is not "does Cialis work" in the abstract, but which of a small number of distinct failure patterns explains their own experience, and whether that pattern is fixable without changing drugs.

The direct answer: In the pivotal trials that supported FDA approval, tadalafil produced successful intercourse attempts in a clear majority of cases, meaningfully more often than placebo, at both the 10 mg and 20 mg on-demand doses. A substantial minority of men, commonly estimated in the range of roughly a third of trial participants, did not reach the trial's success threshold on their first course of treatment. Real-world response is shaped less by the drug's intrinsic pharmacology than by dose titration, timing relative to arousal, and untreated contributors like low testosterone or poorly controlled cardiovascular disease. This article is drawn from FDA labeling, publicly summarized trial data, and aggregated patient review themes, not a new clinical study, and it has not yet received clinician sign-off (see note at the end).

What controlled trials actually establish

The FDA approval of tadalafil rested on a program of randomized, placebo-controlled Phase III trials. Those trials are the highest tier of evidence available for this question, well above anecdotal reviews, and they consistently found that tadalafil produced a statistically significant improvement in erectile function scores and in the proportion of successful sexual attempts compared with placebo, across on-demand doses and in the once-daily regimen.

Secondary summaries of that program, including material reproduced in the original draft of this article, cite specific percentages (for example, success rates in roughly the 65 to 80 percent range on 20 mg versus roughly 35 to 40 percent on placebo, and lower rates in men with diabetes). We were not able to independently verify the specific journal citations attached to those numbers, so we are presenting them here as a directionally accurate summary of a well-established finding, not as a precisely sourced statistic. A reader or clinician who needs the exact figures for a specific population should pull the original registration trial publications or the FDA's medical review of NDA 21-368 rather than relying on the numbers as restated on this page.

What the FDA label itself supports without ambiguity: tadalafil has a longer half-life (about 17.5 hours) and duration of action (up to about 36 hours) than sildenafil or vardenafil, its recommended starting on-demand dose is 10 mg with escalation to 20 mg if needed, and the once-daily 2.5-5 mg regimen is intended for men who prefer not to plan dosing around sexual activity. FDA tadalafil labeling

What "response" means in a trial versus in a review

Trials typically measure response with a diary question asked after each attempt: did the erection last long enough for successful intercourse, yes or no. That is a binary outcome. A man who achieved penetration but felt the experience was mediocre, or who needed several attempts before success, is usually still counted as a responder. This is one reason a person describing Cialis as something that "sort of worked" for them on a forum might have been classified as a full responder in the trial population they resemble. Controlled-trial response rates and satisfaction, as reported informally in reviews, are not measuring exactly the same thing.

What patient reviews add, and where they stop being useful

Aggregator sites and forum threads are not a substitute for trial data, but they surface failure patterns that trials, with their screened populations and structured protocols, do not capture well.

Recurring themes in publicly visible reviews and forum discussion include:

• Men who report failure disproportionately describe taking a single 10 mg dose without escalating to 20 mg, or attempting intercourse within 30 to 45 minutes rather than allowing the full window for onset.
• The 36-hour duration is the most frequently cited reason people prefer tadalafil to shorter-acting PDE5 inhibitors.
• Headache and a delayed muscle or back ache are the side effects most often mentioned as reasons for stopping or switching, more so than flushing or nasal congestion.
• Cost was a barrier before generic tadalafil became widely available in the United States in 2018; that barrier is much smaller with current generic pricing, though specific prices are not something this article can state with confidence and vary by pharmacy and date.

These are consistent patterns, not a measured response rate. Review sites are self-selected, non-randomized, and cannot control for dose, technique, or underlying health status. A reader should treat forum consensus as a source of hypotheses to check with a clinician, not as evidence with the same weight as a randomized trial.

Why real-world response can look lower than trial response

Registration trials exclude men with severe cardiovascular disease, uncontrolled diabetes, and other complicating conditions. Primary care and self-selected online populations include all of those men. It is biologically plausible, and consistent with what is known about PDE5 inhibitor mechanism, that unscreened populations would show a lower response rate than trial populations, because PDE5 inhibitors require some baseline vascular and nerve function plus adequate sexual stimulation to work. We are not aware of a specific, verifiable comparative study quantifying that gap for tadalafil specifically, so that gap should be treated as plausible but not established at any precise figure.

One contributor that does have reasonable clinical support: low testosterone is associated with reduced response to PDE5 inhibitors, and correcting hypogonadism has been reported in the clinical literature to convert some non-responders into responders without changing the PDE5 inhibitor dose. This is a real and clinically actionable mechanism, worth raising with a prescriber if a man has other symptoms of low testosterone (low libido, fatigue, reduced muscle mass) alongside ED, but the exact conversion rate cited in various secondary sources needs to be checked against its original study before being repeated as a specific number.

An evidence-confidence framework for evaluating any Cialis response claim

Before accepting a specific number or story about how well Cialis works, it helps to sort the claim by evidence tier and decide what action, if any, that tier supports.

The practical decision rule that follows from this table: if your own experience matches a pattern described only at the review-and-forum tier (wrong dose, wrong timing, took it with a heavy meal expecting a sildenafil-style food effect), that is worth correcting before assuming the drug does not work for you. If your experience persists after correcting dose and timing, that is the point to move up the table and ask for a guideline-based medical evaluation rather than more anecdote.

Dose-by-dose summary

• 2.5 mg and 5 mg once daily: intended for continuous low-level effect without needing to plan around activity; the 5 mg dose is also FDA-approved for BPH symptoms.
• 10 mg on-demand: the FDA-recommended starting on-demand dose for most men.
• 20 mg on-demand: the ceiling on-demand dose, used when 10 mg is inadequate after correctly administered attempts; taken roughly an hour before anticipated activity per labeling.

Unlike sildenafil, tadalafil's absorption is not meaningfully delayed by food, which several reviewers cite as a practical advantage. This food-interaction difference is described in FDA labeling for the respective drugs and is a reasonable, well-established point of comparison. FDA tadalafil labeling

Side effects that shape whether people keep taking it

Per FDA labeling, the more commonly reported tadalafil side effects include headache, dyspepsia, back pain, myalgia, flushing, and nasal congestion. Reviewers consistently describe headache as the most disruptive of these and myalgia or back ache, appearing roughly half a day to a day after dosing and resolving within about two days, as a side effect that is more specific to tadalafil than to other PDE5 inhibitors. Anyone experiencing a side effect severe enough to consider stopping the drug should discuss it with a prescriber rather than simply discontinuing, since the once-daily lower dose sometimes resolves side effects tied to peak plasma concentration without losing benefit entirely.

Comparing Cialis with sildenafil (Viagra)

Multiple published comparisons of PDE5 inhibitors have found broadly similar efficacy between tadalafil, sildenafil, and vardenafil at their standard doses, with the meaningful differences being duration of action, food interaction, and side effect pattern rather than raw effectiveness. That efficacy-equivalence finding is well established in the clinical literature; the specific study identifiers cited in the original draft of this article could not be verified against the linked sources and are omitted here rather than repeated with an unconfirmed citation. The practical implication for a reader is that switching between tadalafil and sildenafil is reasonably a matter of fit (schedule, tolerance for headache versus a shorter window of activity) rather than one drug being clinically superior.

Who should not take tadalafil, or should take it with caution

Tadalafil is contraindicated with nitrate medications because the combination can cause a severe, dangerous drop in blood pressure. This is an absolute contraindication per FDA labeling, and it applies to any form of nitrate use, including as-needed nitroglycerin for chest pain. Men taking alpha-blockers for BPH should generally use only the lower daily dose and separate dosing from the alpha-blocker as directed on the label, because the combination can also lower blood pressure. Men with severe liver impairment should not use tadalafil. Men with a recent heart attack, unstable angina, or significant heart failure should have that risk assessed by their cardiologist before starting any PDE5 inhibitor; erectile dysfunction itself can be an early marker of cardiovascular disease, which is a separate reason not to skip that conversation. FDA tadalafil labeling

Seek urgent care for an erection lasting more than four hours (priapism), sudden vision or hearing loss, or chest pain, symptoms of a heart attack, or signs of a severe allergic reaction after taking tadalafil.

When Cialis seems to fail: a reasonable next-step sequence

Clinical guidance in this area generally recommends, before concluding a PDE5 inhibitor has failed: confirming the person is taking an adequate dose with correct timing and with actual sexual stimulation (PDE5 inhibitors do not create an erection without arousal), and only then evaluating for underlying contributors such as low testosterone, uncontrolled diabetes, or significant cardiovascular risk factors. If those are addressed and adequate doses still fail, second-line options exist, including intraurethral or injectable prostaglandin therapy and vacuum erection devices, with penile prosthesis as a later option for men who do not respond to or cannot use other treatments. This sequence reflects a general urology guideline framework rather than a specific quoted passage, since the exact guideline text referenced in the original draft could not be verified here.

What is established, what is plausible, and what is not established

Established: Tadalafil has a real, reproducible effect over placebo in randomized trials for erectile dysfunction. It has a distinctly longer duration of action than sildenafil or vardenafil. It carries an absolute contraindication with nitrates and a caution with alpha-blockers.

Plausible but not confirmed on this page: Precise real-world response rates outside trial populations, the exact percentage of hypogonadal non-responders who convert to responders after testosterone correction, and a precise quantitative comparison of tadalafil versus sildenafil preference rates. These claims appear repeatedly in secondary and consumer health literature, but this article could not verify the underlying primary sources, so the specific numbers should be confirmed against original trial and guideline publications before being treated as settled.

Not established: That any single online review pattern (a Reddit thread, a Drugs.com rating) measures a true response rate. These sources are useful for generating hypotheses about common user error, not for estimating how often the drug works.

This article summarizes FDA labeling and general patterns described in publicly available clinical literature and patient reviews. Specific trial citations from an earlier draft of this page could not be independently verified and have been removed or hedged rather than repeated as precise, sourced statistics. This draft is pending qualified clinical review and should not be treated as individualized medical advice; talk to a licensed prescriber about your own dosing, contraindications, and next steps.